BLENREP eDetail/IVA

Ah, the good old IVA. I’ve done a lot of them, but none as complicated as this one. After months and months of working around the complexities of two phase 3 trials for distinct triplets, we got news from the FDA weeks before launch: we could only speak to one trial.

It was a huge undertaking to rework, in the face of a nervous client and a ticking clock.

BLENREP eDetail/IVA

It was a huge undertaking to rework, in the face of a nervous client and a ticking clock.

eDetail Cover

MOA

PFS KM Curve

Efficacy was a showstopper: tripled the mPFS of standard of care.

Dose Mods

Nearly every patient needed dose mods, and the vast majority for ocular adverse events. To many HCPs, this was the most important part of the IVA. We needed a simple way to show this, and this is how we distilled it.